SCHEMBL2654098

SCHEMBL2654098

N#Cc1cc(-c2ccc(CO)cc2)c2c(c1)ncn2-c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 8/20 0.42
SRC P12931 5/20 0.40
AKT1 P31749 2/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.37
KDR P35968 2/20 0.36
ABL1 P00519 1/20 0.36
EGFR P00533 1/20 0.36
CDK1 P06493 1/20 0.36
ABL2 P42684 1/20 0.36
PIK3CD O00329 1/20 0.36
PDPK1 O15530 1/20 0.36
PIK3CA P42336 1/20 0.36
PIK3CB P42338 1/20 0.36
PIK3CG P48736 1/20 0.36
MET P08581 1/20 0.35
KIT P10721 1/20 0.35
FLT3 P36888 1/20 0.35
EGLN2 Q96KS0 1/20 0.35
MAP3K8 P41279 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2656918 0.90 FGFR1 (0.42) FGFR1SRCPTGDR2ABL1EGFR
SCHEMBL2654894 0.89 FGFR1 (0.44) FGFR1SRCPTGDR2KDRMET
SCHEMBL2654102 0.88 FGFR1 (0.47) FGFR1SRCMET
SCHEMBL2654636 0.86 FGFR1 (0.41) FGFR1SRCAKT1KDRPIK3CD
SCHEMBL2654072 0.85 MAPT (0.40) FGFR1SRCAKT1PTGDR2KDR
SCHEMBL2654084 0.84 CYP19A1 (0.43) FGFR1SRCMETHTT
Trifluoroacetic Acid SCHEMBL2662668 0.83 PTGDR2 (0.37) FGFR1SRCPTGDR2ABL1EGFR
SCHEMBL2654014 0.83 KDR (0.54) FGFR1SRCKDRABL1EGFR
SCHEMBL2657491 0.82 FGFR1 (0.45) FGFR1EGLN2
SCHEMBL2655939 0.81 ALDH1A1 (0.51) FGFR1KDRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7700638-B2 1,5,7-trisubstituted benzimidazole derivatives and their use for modulating the GABAA receptor complex N. V. ORGANON (NL) 2010-04-20 US disclosed
US-20070021482-A1 1,5,7-Trisubstituted benzimidazole derivatives and their use for modulating the gabaa receptor complex N.V. ORGANON (NL) 2007-01-25 US disclosed
EP-1678144-A1 1,5,7-TRISUBSTITUTED BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA-a RECEPTOR COMPLEX Akzo Nobel N.V. (NL) 2006-07-12 EP disclosed
WO-2005040131-A1 1,5,7-TRISUBSTITUTED BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX AKZO NOBEL N.V. (NL) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021482-A1 1,5,7-Trisubstituted benzimidazole derivatives and their use for modulating the gabaa receptor complex GABRB1, GABRA5, GABRB2 FGFR1 2259/4885SRC 3544/4885AKT1 3471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.